# PET in Breast Cancer Receiving Neoadjuvant Chemotherapy

> **NCT01396655** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 78 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)

## Key facts

- **NCT ID:** NCT01396655
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-09
- **Final completion:** 2011-06
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01396655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01396655, "PET in Breast Cancer Receiving Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01396655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*